Industry News

FDA Approves Fam-Trastuzumab-Deruxtecan-nxki for HER2-Low Breast Cancer

On August 5, 2022, the U.S Food and Drug Administration (FDA) approved fam-trastuzumab-deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-low breast cancer.

For more information, read the FDA announcement .

Posted 8/5/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us